Key statistics
As of last trade, Cue Biopharma Inc (1UC:STU) traded at 1.61, 304.52% above the 52 week low of 0.398 set on Sep 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.62 |
---|---|
High | 1.62 |
Low | 1.61 |
Bid | 1.57 |
Offer | 1.65 |
Previous close | 1.64 |
Average volume | 0.00 |
---|---|
Shares outstanding | 60.21m |
Free float | 59.88m |
P/E (TTM) | -- |
Market cap | 103.56m USD |
EPS (TTM) | -0.9743 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Announcements
- Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
- Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
- Cue Biopharma Announces Pricing of $12.0 Million Public Offering
- Cue Biopharma Announces Proposed Public Offering
- Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
- Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
- Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Cue Biopharma to Host Business Update Call and Webcast
- Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
- Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
More ▼